Session » Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)
-
Abstract Number: 1458
Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study
-
Abstract Number: 1459
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
-
Abstract Number: 1460
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
-
Abstract Number: 1461
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
-
Abstract Number: 1462
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares